Prime Minister Kassim Majaliwa announced that the Tanzanian government is prepared to collaborate with the Cuban government in establishing a large-scale vaccine production facility in Tanzania. The facility is expected to produce various vaccines, including the hepatitis vaccine.
During his visit to the LABIOFAM Research Center in Cuba, Prime Minister Majaliwa highlighted Cuba's pharmaceutical industry's achievements, particularly in reducing the country's dependency on imported medicines by 60%. The Cuban pharmaceutical industry, which includes the production of plant-based medicines, has played a significant role in this success.
The Prime Minister's visit to Cuba was part of a special mission aimed at strengthening the bilateral relations between Tanzania and Cuba. While visiting the LABIOFAM facility, which manufactures a range of products for human, agricultural, and livestock use, he noted the existing collaboration between LABIOFAM and Tanzania's National Development Corporation (NDC) in Kibaha, Pwani region. The Kibaha facility produces biolarvicides, which are used to spray mosquito breeding grounds across Tanzania and Africa to eradicate mosquitoes and combat malaria.
In light of the visit, Prime Minister Majaliwa directed the Tanzanian Ministry of Health to collaborate with the Tanzanian Embassy in Havana, Cuba, to organize a visit aimed at facilitating discussions with the Cuban Ministry of Health, as well as other relevant industries and institutions involved in pharmaceutical manufacturing in Cuba.
The primary goal of these discussions is to establish a clear framework that will allow these Cuban-produced medicines to be sold in Tanzania, pending approval from the responsible regulatory bodies and institutions overseeing drug use in the country.
Prime Minister Majaliwa specifically mentioned medicines for treating rheumatoid arthritis and diabetic foot ulcers as some of the key products that could benefit Tanzanian patients if approved for use in the country.
.jpeg)
No comments:
Post a Comment